Parkinson’s Drug Complete Response Letter Cites Safety for One Ingredient

By PacConAdmin | July 5, 2023

Amneal Pharmaceuticals’ recent complete response letter (CRL) for its investigational Parkinson’s extended-release drug IPX203 didn’t identify any issues with efficacy or manufacturing — just the safety of one of the two ingredients in the NDA.
Source: Drug Industry Daily

Posted in Drug Industry Daily